バイオ医薬品市場規模、シェア、動向分析レポート：分子別、疾患別、薬剤タイプ別、医薬品開発タイプ別、製剤別、地域別、セグメント予測、2025年～2030年

バイオ医薬品市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のバイオ医薬品市場規模は2030年までに7,408億4,000万米ドルに達し、2025～2030年のCAGRは8.87％で成長すると予測されています。

主要成長促進要因には、慢性疾患の有病率の上昇、精密医療のための生物製剤の採用増加、生物製造技術の進歩などがあります。この成長はさらに、強力な研究開発投資、新規生物製剤の規制当局による承認、バイオシミラー採用の拡大によって支えられています。モノクローナル抗体、細胞・遺伝子治療、遺伝子組換え蛋白質に対する需要の高まりは、腫瘍学、自己免疫疾患、希少疾患の治療アプローチを再構築しています。

バイオ医薬品産業のパイプラインは、遺伝子治療、RNAベースの治療、複数の適応症を対象とする二重特異性抗体などの活発な調査により、引き続き強固なものとなっています。2024年11月にNature Biotechnologyに発表されたCRISPRによる遺伝子編集療法は、鎌状赤血球症やβサラセミア患者において持続的な効果を示しました。

2024年12月、バイオジェンとSamsungバイオエピスはアダリムマブのバイオシミラーのEMA承認を取得し、自己免疫疾患治療における市場競争を拡大しました。この戦略的な動きは、世界的にバイオシミラー医薬品の採用が増加し、購入しやすい価格という課題に対処し、高品質な生物製剤へのアクセスを向上させるものと一致します。欧州やアジアでバイオシミラーの普及が進む中、各社は費用対効果の高い生産戦略を活用し、世界市場での存在感を高めています。

さらに、皮下投与型生物製剤の発売により、投与が簡便になり、輸液センターへの依存度が低下することで、患者の治療体験が大きく変わりつつあります。2025年2月に承認されたアッヴィのインフリキシマブ皮下注製剤は、服薬アドヒアランスと患者満足度を向上させ、大きな市場シェアを獲得すると期待されています。

産業の進歩の一環として、ロンザは、11月20日から22日までシンガポールで開催された2024 Biologics Manufacturing Conferenceにプラチナスポンサーとして参加し、大規模な生物製剤製造におけるイノベーションに焦点を当てました。このイベントでは、シングルユース・バイオリアクター、プロセス強化、AI主導の生物製剤開発など、次世代の有効性の高い治療法を形成する生物製剤製造の動向に焦点が当てられました。

これらの戦略的イニシアチブは、世界の患者転帰の改善を目指したバイオ医薬品の技術革新、市場拡大、規制の進展に重点が置かれていることを強調するものです。

バイオ医薬品市場レポートハイライト

• 分子タイプ別では、モノクローナル抗体が2024年の市場全体の61.05%を占め、その高い特異性、幅広い治療用途、腫瘍学と自己免疫疾患における需要の高まりにより、市場を独占しています。ホルモンセグメントは、内分泌学と代謝性疾患治療における採用の増加により、予測期間中CAGRで堅調に成長すると予測されています。
• 疾患別では、がんの有病率の上昇と生物製剤の承認増加により、2024年にはがん領域が市場全体の31.00%を占め、最大の売上シェアで市場をリードしました。しかし、免疫学セグメントは予測期間中に最も速い速度で成長すると予想されています。
• 薬剤タイプ別では、プロプライエタリ（ブランド）バイオ医薬品が2024年に市場全体の77.86%を占め、最大の売上シェアを占めました。しかし、バイオシミラーは、規制当局の承認とコスト削減イニシアチブの増加により、予測期間中に最も速いCAGRを記録すると予想されます。
• 医薬品開発タイプ別にみると、2024年にはバイオ医薬品開発のアウトソーシングが市場全体の56.15%を占め、市場を独占しています。
• 製剤別では、注射用生物製剤（静脈注射、IM、SC）が2024年に最大の売上シェアを占め、市場の92.55%を占めました。しかし、吸入と経鼻生物製剤は、非侵襲的ドラッグデリバリーの進歩により大きな成長が見込まれています。
• 投与経路別では、非経口投与（静脈注射、筋肉内注射、筋肉内注射）が2024年に88.74%のシェアで市場をリードしました。吸入と経鼻投与は、予測期間中に牽引力を増すと予想されます。
• 処方タイプ別では、処方薬が2024年に市場を独占し、総売上の96.90%を占めたが、これは厳しい規制監督と生物製剤治療の複雑さによる。
• 流通チャネル別では、病院や専門クリニックを含む非小売チャネルが2024年に支配的な流通チャネルとして浮上し、総売上の55.70%を占めました。
• バイオ医薬品産業の主要企業には、アムジェン社、Pfizer、Novartis、サノフィ社、Merck、ロシュ・ホールディング社、バイオジェン社、アストラゼネカ社、イーライリリー社、Bayerが含まれます。
• 2024年6月、リジェネロン・ファーマシューティカルズインクは、2歳以上の活動性の多関節型若年性特発性関節炎（pJIA）の治療としてケブザラ（一般名：サリルマブ）が米国FDAより承認されたことを発表しました。今回の承認は、この慢性炎症性疾患に罹患している小児に新たな治療選択肢を提供するものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 バイオ医薬品市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 価格分析

第4章 バイオ医薬品市場：分子タイプビジネス分析

• 分子タイプ市場シェア、2024年と2030年
• 分子タイプセグメントダッシュボード
• 市場規模、予測、動向分析（分子タイプ別、2018～2030年）
• モノクローナル抗体
• インターフェロン
• インスリン
• 成長因子と凝固因子
• エリスロポエチン
• ワクチン
• ホルモン
• その他

第5章 バイオ医薬品市場：疾患ビジネス分析

• 疾病市場シェア、2024年と2030年
• 疾患セグメントダッシュボード
• 市場規模、予測、動向分析（疾患別、2018～2030年）
• 腫瘍学
• 血液疾患
• 代謝性疾患
• 感染症
• 心血管疾患
• 神経疾患
• 免疫学
• その他

第6章 バイオ医薬品市場：医薬品タイプ別ビジネス分析

• 医薬品タイプ別市場シェア、2024年と2030年
• 医薬品タイプセグメントダッシュボード
• 市場規模、予測、動向分析（医薬品タイプ別、2018～2030年）
• 独自ブランド

第7章 バイオ医薬品市場：医薬品開発タイプビジネス分析

• 医薬品開発タイプ市場シェア、2024年と2030年
• 医薬品開発タイプセグメントダッシュボード
• 市場規模、予測、動向分析（医薬品開発タイプ別、2018～2030年）
• アウトソーシング
• 社内

第8章 バイオ医薬品市場：製剤ビジネス分析

• 製剤市場シェア、2024年と2030年
• 製剤セグメントダッシュボード
• 市場規模、予測、動向分析（製剤別、2018～2030年）
• 注射剤（IV、IM、SC）
• 吸入/鼻腔スプレー
• その他

第9章 バイオ医薬品市場：投与経路ビジネス分析

• 投与経路市場シェア、2024年と2030年
• 投与経路セグメントダッシュボード
• 市場規模、予測、動向分析（投与経路別、2018～2030年）
• 非経口（IV、IM、SC）
• 吸入/鼻腔
• その他

第10章 バイオ医薬品市場：処方タイプビジネス分析

• 処方タイプ別市場シェア、2024年と2030年
• 処方タイプセグメントダッシュボード
• 市場規模、予測、動向分析（処方タイプ別、2018～2030年）
• 処方薬
• 市販薬（OTC）

第11章 バイオ医薬品市場：流通チャネルビジネス分析

• 流通チャネル市場シェア、2024年と2030年
• 流通チャネルセグメントダッシュボード
• 市場規模と予測と動向分析（流通チャネル別、2018～2030年）
• 小売
• 非小売

第12章 バイオ医薬品市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第13章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • GSK plc.
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Amgen Inc.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global Biopharmaceutical Market, by Region, 2018 - 2030 (USD Million)
• Table 4 Global Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 5 Global Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 6 Global Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 7 Global Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 8 Global Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 9 Global Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 10 Global Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 11 Global Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 12 North America Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
• Table 13 North America Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 14 North America Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 15 North America Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 16 North America Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 17 North America Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 18 North America Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 19 North America Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 20 North America Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 21 US Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 22 US Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 23 US Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 24 US Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 25 US Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 26 US Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 27 US Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 28 US Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 29 Canada Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 30 Canada Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 31 Canada Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 32 Canada Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 33 Canada Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 34 Canada Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 35 Canada Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 36 Canada Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 37 Mexico Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 38 Mexico Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 39 Mexico Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 40 Mexico Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 41 Mexico Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 42 Mexico Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 43 Mexico Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 44 Mexico Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 45 Europe Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
• Table 46 Europe Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 47 Europe Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 48 Europe Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 49 Europe Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 50 Europe Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 51 Europe Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 52 Europe Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 53 Europe Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 54 UK Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 55 UK Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 56 UK Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 57 UK Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 58 UK Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 59 UK Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 60 UK Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 61 UK Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 62 Germany Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 63 Germany Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 64 Germany Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 65 Germany Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 66 Germany Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 67 Germany Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 68 Germany Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 69 Germany Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 70 France Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 71 France Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 72 France Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 73 France Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 74 France Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 75 France Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 76 France Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 77 France Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 78 Italy Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 79 Italy Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 80 Italy Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 81 Italy Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 82 Italy Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 83 Italy Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 84 Italy Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 85 Italy Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 86 Spain Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 87 Spain Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 88 Spain Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 89 Spain Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 90 Spain Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 91 Spain Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 92 Spain Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 93 Spain Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 94 Norway Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 95 Norway Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 96 Norway Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 97 Norway Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 98 Norway Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 99 Norway Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 100 Norway Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 101 Norway Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 102 Denmark Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 103 Denmark Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 104 Denmark Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 105 Denmark Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 106 Denmark Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 107 Denmark Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 108 Denmark Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 109 Denmark Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 110 Sweden Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 111 Sweden Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 112 Sweden Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 113 Sweden Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 114 Sweden Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 115 Sweden Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 116 Sweden Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 117 Sweden Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 118 Asia Pacific Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
• Table 119 Asia Pacific Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 120 Asia Pacific Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 121 Asia Pacific Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 122 Asia Pacific Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 123 Asia Pacific Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 124 Asia Pacific Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 125 Asia Pacific Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 126 Asia Pacific Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 127 Japan Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 128 Japan Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 129 Japan Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 130 Japan Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 131 Japan Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 132 Japan Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 133 Japan Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 134 Japan Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 135 China Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 136 China Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 137 China Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 138 China Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 139 China Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 140 China Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 141 China Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 142 China Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 143 India Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 144 India Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 145 India Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 146 India Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 147 India Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 148 India Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 149 India Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 150 India Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 151 Australia Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 152 Australia Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 153 Australia Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 154 Australia Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 155 Australia Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 156 Australia Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 157 Australia Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 158 Australia Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 159 South Korea Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 160 South Korea Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 161 South Korea Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 162 South Korea Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 163 South Korea Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 164 South Korea Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 165 South Korea Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 166 South Korea Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 167 Thailand Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 168 Thailand Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 169 Thailand Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 170 Thailand Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 171 Thailand Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 172 Thailand Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 173 Thailand Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 174 Thailand Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 175 Latin America Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
• Table 176 Latin America Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 177 Latin America Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 178 Latin America Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 179 Latin America Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 180 Latin America Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 181 Latin America Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 182 Latin America Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 183 Latin America Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 184 Brazil Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 185 Brazil Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 186 Brazil Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 187 Brazil Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 188 Brazil Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 189 Brazil Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 190 Brazil Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 191 Brazil Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 192 Argentina Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 193 Argentina Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 194 Argentina Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 195 Argentina Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 196 Argentina Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 197 Argentina Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 198 Argentina Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 199 Argentina Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 200 Middle East & Africa Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
• Table 201 Middle East & Africa Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 202 Middle East & Africa Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 203 Middle East & Africa Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 204 Middle East & Africa Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 205 Middle East & Africa Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 206 Middle East & Africa Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 207 Middle East & Africa Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 208 Middle East & Africa Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 209 South Africa Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 210 South Africa Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 211 South Africa Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 212 South Africa Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 213 South Africa Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 214 South Africa Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 215 South Africa Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 216 South Africa Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 217 Saudi Arabia Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 218 Saudi Arabia Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 219 Saudi Arabia Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 220 Saudi Arabia Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 221 Saudi Arabia Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 222 Saudi Arabia Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 223 Saudi Arabia Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 224 Saudi Arabia Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 225 UAE Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 226 UAE Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 227 UAE Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 228 UAE Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 229 UAE Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 230 UAE Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 231 UAE Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 232 UAE Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
• Table 233 Kuwait Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
• Table 234 Kuwait Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
• Table 235 Kuwait Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
• Table 236 Kuwait Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
• Table 237 Kuwait Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
• Table 238 Kuwait Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 239 Kuwait Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
• Table 240 Kuwait Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Biopharmaceutical market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 QFD modelling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Segment snapshot
• Fig. 10 Segment snapshot
• Fig. 11 Segment snapshot
• Fig. 12 Segment snapshot
• Fig. 13 Segment snapshot
• Fig. 14 Competitive landscape snapshot
• Fig. 15 Parent market value, 2024 (USD billion)
• Fig. 16 Market dynamics
• Fig. 17 Global large pharma R&D spending in 2018 - 2023 (USD Billion)
• Fig. 18 Porter's five forces analysis
• Fig. 19 PESTLE analysis
• Fig. 20 Biopharmaceutical market: Molecule type outlook and key takeaways
• Fig. 21 Biopharmaceutical market: Molecule type movement analysis
• Fig. 22 Monoclonal antibody market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 23 Interferon market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 24 Insulin market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 25 Growth and coagulation factor market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 26 Erythropoietin market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 27 Vaccines market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 28 Hormone market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 30 Biopharmaceutical market: Disease outlook and key takeaways
• Fig. 31 Biopharmaceutical market: Disease movement analysis
• Fig. 32 Oncology market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 33 Blood disorder market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 34 Metabolic disease market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 35 Infectious disease market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 36 Cardiovascular disease market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 37 Neurological disease market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 38 Immunology market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 40 Biopharmaceutical market: Drug Type outlook and key takeaways
• Fig. 41 Biopharmaceutical market: Drug type movement analysis
• Fig. 42 Proprietary (Branded) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 43 Biosimilars market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 44 Biopharmaceutical market: Drug development type outlook and key takeaways
• Fig. 45 Biopharmaceutical market: Drug development type movement analysis
• Fig. 46 Outsource market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 47 In-house market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 48 Biopharmaceutical market: Formulation outlook and key takeaways
• Fig. 49 Biopharmaceutical market: Formulation movement analysis
• Fig. 50 Injectable market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 51 Inhalation/nasal sprays market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 52 Other formulations market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 53 Biopharmaceutical market: Prescription outlook and key takeaways
• Fig. 54 Biopharmaceutical market: Prescription movement analysis
• Fig. 55 Prescription medicines market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 56 OTC market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 57 Biopharmaceuticals market: Route of administration outlook and key takeaways
• Fig. 58 Biopharmaceuticals market: Route of administration movement analysis
• Fig. 59 Parenteral market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 60 Inhalations/Nasal market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 61 Other routes of administration market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 62 Biopharmaceuticals market Sales channel market outlook and key takeaways
• Fig. 63 Biopharmaceuticals market Sales channel market movement analysis
• Fig. 64 Retail market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 65 Non-retail market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 66 Biopharmaceutical market revenue, by region, 2024 & 2030 (USD Billion)
• Fig. 67 Regional marketplace: Key takeaways
• Fig. 68 North America biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 69 Key country dynamics
• Fig. 70 U.S. biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 71 Cancer incidence, 2022-2045
• Fig. 72 U.S. healthcare system: money flow
• Fig. 73 Key country dynamics
• Fig. 74 Canada biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 75 Cancer incidence, 2022-2045
• Fig. 76 Key country dynamics
• Fig. 77 Mexico biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 78 Cancer incidence, 2022-2045
• Fig. 79 Regulatory framework
• Fig. 80 Europe biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 81 Obesity and diabetes in European nations
• Fig. 82 Causes of mortality in Europe
• Fig. 83 Key country dynamics
• Fig. 84 UK biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 85 Cancer incidence, 2022-2045
• Fig. 86 Key country dynamics
• Fig. 87 Germany biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 88 Cancer incidence, 2022-2045
• Fig. 89 R&D spending
• Fig. 90 Exclusivity formula
• Fig. 91 Germany insurance coverage
• Fig. 92 Key country dynamics
• Fig. 93 France biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 94 Cancer incidence, 2022-2045
• Fig. 95 Key country dynamics
• Fig. 96 Italy biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 97 Cancer incidence, 2022-2045
• Fig. 98 Key country dynamics
• Fig. 99 Spain biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 100 Cancer incidence, 2022-2045
• Fig. 101 Key country dynamics
• Fig. 102 Denmark biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 103 Cancer Incidence, 2022-2045
• Fig. 104 Key country dynamics
• Fig. 105 Sweden biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 106 Cancer incidence 2022-2045
• Fig. 107 Key country dynamics
• Fig. 108 Norway biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 109 Cancer incidence, 2022-2045
• Fig. 110 Rest of Europe biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 111 Asia Pacific biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 112 Key country dynamics
• Fig. 113 Japan biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 114 Cancer incidence, 2022-2045
• Fig. 115 Japan pharmaceutical registration
• Fig. 116 Key country dynamics
• Fig. 117 China biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 118 Cancer incidence, 2022-2045
• Fig. 119 Regulatory details: China
• Fig. 120 Key country dynamics
• Fig. 121 India biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 122 Cancer incidence, 2018 - 2030
• Fig. 123 Key country dynamics
• Fig. 124 Australia biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 125 Cancer incidence, 2018 - 2030
• Fig. 126 Key country dynamics
• Fig. 127 Thailand biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 128 Cancer incidence, 2018 - 2030
• Fig. 129 Key country dynamics
• Fig. 130 South Korea biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 131 Cancer incidence, 2018 - 2030
• Fig. 132 Rest of Asia Pacific biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 133 Latin America biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 134 Key country dynamics
• Fig. 135 Brazil biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 136 Cancer incidence, 2018 - 2030
• Fig. 137 Key country dynamics
• Fig. 138 Argentina biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 139 Cancer incidence, 2018 - 2030
• Fig. 140 Rest of Latin America biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 141 MEA biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 142 Key country dynamics
• Fig. 143 South Africa biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 144 Cancer incidence, 2018 - 2030
• Fig. 145 Key country dynamics
• Fig. 146 Saudi Arabia biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 147 Cancer incidence, 2018 - 2030
• Fig. 148 Key country dynamics
• Fig. 149 UAE biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 150 Cancer incidence, 2018 - 2030
• Fig. 151 UAE import and export details
• Fig. 152 Key country dynamics
• Fig. 153 Kuwait biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 154 Cancer incidence, 2018 - 2030
• Fig. 155 Kuwait imports and export details
• Fig. 156 Rest of MEA biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 157 Company/competition categorization
• Fig. 160 Strategy mapping

Biopharmaceutical Market Growth & Trends:

The global biopharmaceutical market size is anticipated to reach USD 740.84 billion by 2030, growing at a CAGR of 8.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key growth drivers include the rising prevalence of chronic diseases, increasing adoption of biologics for precision medicine, and advancements in biomanufacturing technologies. The growth is further supported by strong research and development investments, regulatory approvals for novel biologics, and expanding biosimilar adoption. The growing demand for monoclonal antibodies, cell and gene therapies, and recombinant proteins is reshaping treatment approaches across oncology, autoimmune diseases, and rare disorders.

The biopharmaceutical industry pipeline remains robust, with active research in gene therapies, RNA-based therapeutics, and bispecific antibodies targeting multiple indications. A notable breakthrough includes CRISPR-based gene editing therapies published in Nature Biotechnology in November 2024, demonstrating durable responses in sickle cell disease and beta-thalassemia patients.

In December 2024, Biogen and Samsung Bioepis secured EMA approval for their biosimilar adalimumab, expanding market competition in autoimmune disease treatment. This strategic move aligns with increasing global biosimilar adoption, addressing affordability challenges and improving access to high-quality biologics. With biosimilar penetration increasing across Europe and Asia, companies are leveraging cost-effective production strategies to enhance global market presence.

Additionally, the launch of subcutaneous biologics is transforming patient treatment experiences, offering convenient administration and reducing dependency on infusion centers. AbbVie's subcutaneous formulation of infliximab, approved in February 2025, is expected to capture significant market share, improving adherence and patient satisfaction.

As part of industry advancements, Lonza participated as a Platinum Sponsor at the 2024 Biologics Manufacturing Conference held in Singapore from November 20-22, focusing on innovations in large-scale biologics production. The event highlighted biopharma manufacturing trends, including single-use bioreactors, process intensification, and AI-driven biologics development, shaping the next generation of high-efficacy therapies.

These strategic initiatives underscore the growing emphasis on biopharmaceutical innovation, market expansion, and regulatory advancements aimed at improving patient outcomes worldwide.

Biopharmaceutical Market Report Highlights:

• Based on molecule type, monoclonal antibodies dominated the market in 2024, accounting for 61.05% of the total revenue due to their high specificity, broad therapeutic applications, and growing demand in oncology and autoimmune disorders. The hormone segment is projected to grow at a robust CAGR over the forecast period, driven by increasing adoption in endocrinology and metabolic disease treatments.
• Based on disease, oncology led the market with the largest revenue share in 2024, accounting for 31.00% of the total market due to the rising prevalence of cancer and increasing approvals of biologic therapies. However, the immunology segment is expected to grow at the fastest rate over the forecast period.
• Based on drug type, proprietary (branded) biopharmaceuticals held the largest revenue share in 2024, comprising 77.86% of the total market, attributed to continuous R&D investments and strong patent protection. However, biosimilars are expected to witness the fastest CAGR over the forecast period due to regulatory approvals and increasing cost-saving initiatives.
• Based on drug development type, outsourced biopharmaceutical development dominated the market in 2024, accounting for 56.15% of the total revenue as companies increasingly leverage contract development and manufacturing organizations (CDMOs) to optimize costs and accelerate commercialization.
• Based on formulation, injectable biologics (IV, IM, SC) held the largest revenue share in 2024, comprising 92.55% of the market, driven by their systemic absorption and effectiveness. However, inhalation and nasal biologics are expected to witness significant growth due to advancements in non-invasive drug delivery.
• Based on route of administration, parenteral administration (IV, IM, SC) led the market in 2024, with an 88.74% share, as most biologics require systemic delivery. Inhalation and nasal routes are expected to gain traction over the forecast period.
• Based on prescription type, prescription medicines dominated the market in 2024, accounting for 96.90% of the total revenue due to stringent regulatory oversight and the complexity of biologic therapies.
• Based on sales channel, non-retail channels, including hospitals and specialty clinics, emerged as the dominant distribution channel in 2024, accounting for 55.70% of total revenue, reflecting the need for controlled administration and storage of biologics.
• Key players operating in the biopharmaceutical industry include Amgen Inc.; Pfizer Inc.; Novartis AG; Sanofi; Merck & Co.; Roche Holding AG; Biogen Inc.; AstraZeneca; Eli Lilly and Company; and Bayer AG.
• In June 2024, Regeneron Pharmaceuticals, Inc. announced the approval of Kevzara (sarilumab) by the U.S. FDA for the treatment of active Polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years and older. This approval provides a new treatment option for children affected by this chronic inflammatory condition.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule Type
  • 1.2.2. Disease
  • 1.2.3. Drug Type
  • 1.2.4. Drug Development Type
  • 1.2.5. Formulation
  • 1.2.6. Route of Administration
  • 1.2.7. Prescription Type
  • 1.2.8. Sales Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Pricing Analysis

Chapter 4. Biopharmaceutical Market: Molecule Type Business Analysis

• 4.1. Molecule Type Market Share, 2024 & 2030
• 4.2. Molecule Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type , 2018 to 2030 (USD Million)
• 4.4. Monoclonal Antibody
  • 4.4.1. Monoclonal Antibody Market, 2018 - 2030 (USD Million)
• 4.5. Interferon
  • 4.5.1. Interferon Market, 2018 - 2030 (USD Million)
• 4.6. Insulin
  • 4.6.1. Insulin Market, 2018 - 2030 (USD Million)
• 4.7. Growth and Coagulation Factor
  • 4.7.1. Growth and Coagulation Factor Market, 2018 - 2030 (USD Million)
• 4.8. Erythropoietin
  • 4.8.1. Erythropoietin Market, 2018 - 2030 (USD Million)
• 4.9. Vaccine
  • 4.9.1. Vaccine Market, 2018 - 2030 (USD Million)
• 4.10. Hormone
  • 4.10.1. Hormone Market, 2018 - 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Other Type Market, 2018 - 2030 (USD Million)

Chapter 5. Biopharmaceutical Market: Disease Business Analysis

• 5.1. Disease Market Share, 2024 & 2030
• 5.2. Disease Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology Market, 2018 - 2030 (USD Million)
• 5.5. Blood Disorder
  • 5.5.1. Blood Disorder Market, 2018 - 2030 (USD Million)
• 5.6. Metabolic Disease
  • 5.6.1. Metabolic Disease Market, 2018 - 2030 (USD Million)
• 5.7. Infectious Disease
  • 5.7.1. Infectious Disease Market, 2018 - 2030 (USD Million)
• 5.8. Cardiovascular Disease
  • 5.8.1. Cardiovascular Disease Market, 2018 - 2030 (USD Million)
• 5.9. Neurological Disease
  • 5.9.1. Neurological Disease Market, 2018 - 2030 (USD Million)
• 5.10. Immunology
  • 5.10.1. Immunology Market, 2018 - 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Other Type Market, 2018 - 2030 (USD Million)

Chapter 6. Biopharmaceutical Market: Drug Type Business Analysis

• 6.1. Drug Type Market Share, 2024 & 2030
• 6.2. Drug Type Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
• 6.4. Proprietary (Branded)
  • 6.4.1. Proprietary (Branded) Market, 2018 - 2030 (USD Million)
  • 6.4.2. Biosimilars
    • 6.4.2.1. Biosimilars Market, 2018 - 2030 (USD Million)

Chapter 7. Biopharmaceutical Market: Drug Development Type Business Analysis

• 7.1. Drug Development Type Market Share, 2024 & 2030
• 7.2. Drug Development Type Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Drug Development Type, 2018 to 2030 (USD Million)
• 7.4. Outsource
  • 7.4.1. Outsource Market, 2018 - 2030 (USD Million)
• 7.5. In-house
  • 7.5.1. In-house Market, 2018 - 2030 (USD Million)

Chapter 8. Biopharmaceutical Market: Formulation Business Analysis

• 8.1. Formulation Market Share, 2024 & 2030
• 8.2. Formulation Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2018 to 2030 (USD Million)
• 8.4. Injectables (IV, IM, SC)
  • 8.4.1. Injectables (IV, IM, SC) Market, 2018 - 2030 (USD Million)
• 8.5. Inhalation/Nasal Sprays
  • 8.5.1. Inhalation/Nasal Sprays Market, 2018 - 2030 (USD Million)
• 8.6. Other Formulations
  • 8.6.1. Other Formulations Market, 2018 - 2030 (USD Million)

Chapter 9. Biopharmaceutical Market: Route of Administration Business Analysis

• 9.1. Route of Administration Market Share, 2024 & 2030
• 9.2. Route of Administration Segment Dashboard
• 9.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 9.4. Parenteral (IV, IM, SC)
  • 9.4.1. Parenteral (IV, IM, SC) Market, 2018 - 2030 (USD Million)
• 9.5. Inhalation/Nasal
  • 9.5.1. Inhalation/Nasal Market, 2018 - 2030 (USD Million)
• 9.6. Other Routes
  • 9.6.1. Other Routes Market, 2018 - 2030 (USD Million)

Chapter 10. Biopharmaceutical Market: Prescription Type Business Analysis

• 10.1. Prescription Type Market Share, 2024 & 2030
• 10.2. Prescription Type Segment Dashboard
• 10.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2018 to 2030 (USD Million)
• 10.4. Prescription Medicines
  • 10.4.1. Prescription Medicines Market, 2018 - 2030 (USD Million)
• 10.5. Over-the-counter (OTC) Medicines
  • 10.5.1. Over-the-counter (OTC) Medicines Market, 2018 - 2030 (USD Million)

Chapter 11. Biopharmaceutical Market: Sales Channel Business Analysis

• 11.1. Sales Channel Market Share, 2024 & 2030
• 11.2. Sales Channel Segment Dashboard
• 11.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
• 11.4. Retail Pharmacies
  • 11.4.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 11.5. Non-retail
  • 11.5.1. Non-retail Market, 2018 - 2030 (USD Million)

Chapter 12. Biopharmaceutical Market: Regional Estimates & Trend Analysis

• 12.1. Regional Market Share Analysis, 2024 & 2030
• 12.2. Regional Market Dashboard
• 12.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 12.4. North America
  • 12.4.1. North America Biopharmaceutical Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 12.4.2. U.S.
    • 12.4.2.1. Key Country Dynamics
    • 12.4.2.2. Target Disease Prevalence
    • 12.4.2.3. Regulatory Framework
    • 12.4.2.4. Reimbursement Framework
    • 12.4.2.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.4.3. Canada
    • 12.4.3.1. Key Country Dynamics
    • 12.4.3.2. Target Disease Prevalence
    • 12.4.3.3. Regulatory Framework
    • 12.4.3.4. Reimbursement Framework
    • 12.4.3.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.4.4. Mexico
    • 12.4.4.1. Key Country Dynamics
    • 12.4.4.2. Target Disease Prevalence
    • 12.4.4.3. Regulatory Framework
    • 12.4.4.4. Reimbursement Framework
    • 12.4.4.5. Mexico Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.5. Europe
  • 12.5.1. Europe Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.2. UK
    • 12.5.2.1. Key Country Dynamics
    • 12.5.2.2. Target Disease Prevalence
    • 12.5.2.3. Regulatory Framework
    • 12.5.2.4. Reimbursement Framework
    • 12.5.2.5. Uk Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.3. Germany
    • 12.5.3.1. Key Country Dynamics
    • 12.5.3.2. Target Disease Prevalence
    • 12.5.3.3. Regulatory Framework
    • 12.5.3.4. Reimbursement Framework
    • 12.5.3.5. Germany Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.4. France
    • 12.5.4.1. Key Country Dynamics
    • 12.5.4.2. Target Disease Prevalence
    • 12.5.4.3. Regulatory Framework
    • 12.5.4.4. Reimbursement Framework
    • 12.5.4.5. France Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.5. Italy
    • 12.5.5.1. Key Country Dynamics
    • 12.5.5.2. Target Disease Prevalence
    • 12.5.5.3. Regulatory Framework
    • 12.5.5.4. Reimbursement Framework
    • 12.5.5.5. Italy Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.6. Spain
    • 12.5.6.1. Key Country Dynamics
    • 12.5.6.2. Target Disease Prevalence
    • 12.5.6.3. Regulatory Framework
    • 12.5.6.4. Reimbursement Framework
    • 12.5.6.5. Spain Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.7. Denmark
    • 12.5.7.1. Key Country Dynamics
    • 12.5.7.2. Target Disease Prevalence
    • 12.5.7.3. Regulatory Framework
    • 12.5.7.4. Reimbursement Framework
    • 12.5.7.5. Denmark Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.8. Sweden
    • 12.5.8.1. Key Country Dynamics
    • 12.5.8.2. Target Disease Prevalence
    • 12.5.8.3. Regulatory Framework
    • 12.5.8.4. Reimbursement Framework
    • 12.5.8.5. Sweden Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5.9. Norway
    • 12.5.9.1. Key Country Dynamics
    • 12.5.9.2. Target Disease Prevalence
    • 12.5.9.3. Regulatory Framework
    • 12.5.9.4. Reimbursement Framework
    • 12.5.9.5. Norway Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.6. Asia Pacific
  • 12.6.1. Asia Pacific Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.2. Japan
    • 12.6.2.1. Key Country Dynamics
    • 12.6.2.2. Target Disease Prevalence
    • 12.6.2.3. Regulatory Framework
    • 12.6.2.4. Reimbursement Framework
    • 12.6.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.3. China
    • 12.6.3.1. Key Country Dynamics
    • 12.6.3.2. Target Disease Prevalence
    • 12.6.3.3. Regulatory Framework
    • 12.6.3.4. Reimbursement Framework
    • 12.6.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.4. India
    • 12.6.4.1. Key Country Dynamics
    • 12.6.4.2. Target Disease Prevalence
    • 12.6.4.3. Regulatory Framework
    • 12.6.4.4. Reimbursement Framework
    • 12.6.4.5. India Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.5. Australia
    • 12.6.5.1. Key Country Dynamics
    • 12.6.5.2. Target Disease Prevalence
    • 12.6.5.3. Regulatory Framework
    • 12.6.5.4. Reimbursement Framework
    • 12.6.5.5. Australia Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.6. South Korea
    • 12.6.6.1. Key Country Dynamics
    • 12.6.6.2. Target Disease Prevalence
    • 12.6.6.3. Regulatory Framework
    • 12.6.6.4. Reimbursement Framework
    • 12.6.6.5. South Korea Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6.7. Thailand
    • 12.6.7.1. Key Country Dynamics
    • 12.6.7.2. Target Disease Prevalence
    • 12.6.7.3. Regulatory Framework
    • 12.6.7.4. Reimbursement Framework
    • 12.6.7.5. Thailand Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.7. Latin America
  • 12.7.1. Latin America Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.7.2. Brazil
    • 12.7.2.1. Key Country Dynamics
    • 12.7.2.2. Target Disease Prevalence
    • 12.7.2.3. Regulatory Framework
    • 12.7.2.4. Reimbursement Framework
    • 12.7.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.7.3. Argentina
    • 12.7.3.1. Key Country Dynamics
    • 12.7.3.2. Target Disease Prevalence
    • 12.7.3.3. Regulatory Framework
    • 12.7.3.4. Reimbursement Framework
    • 12.7.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 12.8. Middle East and Africa
  • 12.8.1. Middle East and Africa Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.2. South Africa
    • 12.8.2.1. Key Country Dynamics
    • 12.8.2.2. Target Disease Prevalence
    • 12.8.2.3. Regulatory Framework
    • 12.8.2.4. Reimbursement Framework
    • 12.8.2.5. South Africa Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.3. Saudi Arabia
    • 12.8.3.1. Key Country Dynamics
    • 12.8.3.2. Target Disease Prevalence
    • 12.8.3.3. Regulatory Framework
    • 12.8.3.4. Reimbursement Framework
    • 12.8.3.5. Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.4. UAE
    • 12.8.4.1. Key Country Dynamics
    • 12.8.4.2. Target Disease Prevalence
    • 12.8.4.3. Regulatory Framework
    • 12.8.4.4. Reimbursement Framework
    • 12.8.4.5. UAE Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8.5. Kuwait
    • 12.8.5.1. Key Country Dynamics
    • 12.8.5.2. Target Disease Prevalence
    • 12.8.5.3. Regulatory Framework
    • 12.8.5.4. Reimbursement Framework
    • 12.8.5.5. Kuwait Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 13. Competitive Landscape

• 13.1. Participant Overview
• 13.2. Company Market Position Analysis
• 13.3. Company Categorization
• 13.4. Strategy Mapping
• 13.5. Company Profiles/Listing
  • 13.5.1. F. Hoffmann-La Roche Ltd
    • 13.5.1.1. Overview
    • 13.5.1.2. Financial Performance
    • 13.5.1.3. Product Benchmarking
    • 13.5.1.4. Strategic Initiatives
  • 13.5.2. Novartis AG
    • 13.5.2.1. Overview
    • 13.5.2.2. Financial Performance
    • 13.5.2.3. Product Benchmarking
    • 13.5.2.4. Strategic Initiatives
  • 13.5.3. AbbVie Inc.
    • 13.5.3.1. Overview
    • 13.5.3.2. Financial Performance
    • 13.5.3.3. Product Benchmarking
    • 13.5.3.4. Strategic Initiatives
  • 13.5.4. Johnson & Johnson Services, Inc.
    • 13.5.4.1. Overview
    • 13.5.4.2. Financial Performance
    • 13.5.4.3. Product Benchmarking
    • 13.5.4.4. Strategic Initiatives
  • 13.5.5. Merck & Co., Inc.
    • 13.5.5.1. Overview
    • 13.5.5.2. Financial Performance
    • 13.5.5.3. Product Benchmarking
    • 13.5.5.4. Strategic Initiatives
  • 13.5.6. Pfizer Inc.
    • 13.5.6.1. Overview
    • 13.5.6.2. Financial Performance
    • 13.5.6.3. Product Benchmarking
    • 13.5.6.4. Strategic Initiatives
  • 13.5.7. Bristol-Myers Squibb Company
    • 13.5.7.1. Overview
    • 13.5.7.2. Financial Performance
    • 13.5.7.3. Product Benchmarking
    • 13.5.7.4. Strategic Initiatives
  • 13.5.8. Sanofi
    • 13.5.8.1. Overview
    • 13.5.8.2. Financial Performance
    • 13.5.8.3. Product Benchmarking
    • 13.5.8.4. Strategic Initiatives
  • 13.5.9. GSK plc.
    • 13.5.9.1. Overview
    • 13.5.9.2. Financial Performance
    • 13.5.9.3. Product Benchmarking
    • 13.5.9.4. Strategic Initiatives
  • 13.5.10. AstraZeneca
    • 13.5.10.1. Overview
    • 13.5.10.2. Financial Performance
    • 13.5.10.3. Product Benchmarking
    • 13.5.10.4. Strategic Initiatives
  • 13.5.11. Takeda Pharmaceutical Company Limited
    • 13.5.11.1. Overview
    • 13.5.11.2. Financial Performance
    • 13.5.11.3. Product Benchmarking
    • 13.5.11.4. Strategic Initiatives
  • 13.5.12. Biogen
    • 13.5.12.1. Overview
    • 13.5.12.2. Financial Performance
    • 13.5.12.3. Product Benchmarking
    • 13.5.12.4. Strategic Initiatives
  • 13.5.13. Eli Lilly and Company
    • 13.5.13.1. Overview
    • 13.5.13.2. Financial Performance
    • 13.5.13.3. Product Benchmarking
    • 13.5.13.4. Strategic Initiatives
  • 13.5.14. Novo Nordisk A/S
    • 13.5.14.1. Overview
    • 13.5.14.2. Financial Performance
    • 13.5.14.3. Product Benchmarking
    • 13.5.14.4. Strategic Initiatives
  • 13.5.15. Amgen Inc.
    • 13.5.15.1. Overview
    • 13.5.15.2. Financial Performance
    • 13.5.15.3. Product Benchmarking
    • 13.5.15.4. Strategic Initiatives